Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AC Immune SA - Common Stock (NQ:ACIU)

2.030 +0.020 (+1.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AC Immune SA - Common Stock

< Previous 1 2 Next >
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
From AC Immune SA
Via GlobeNewswire
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
From AC Immune SA
Via GlobeNewswire
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
From AC Immune SA
Via GlobeNewswire
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023
From AC Immune SA
Via GlobeNewswire
AC Immune SA Appoints New Chief Medical Officer
From AC Immune SA
Via GlobeNewswire
AC Immune Showcasing Precision Medicine Programs at AAIC 2023
From AC Immune SA
Via GlobeNewswire
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease
From AC Immune SA
Via GlobeNewswire
AC Immune Holds Annual General Meeting of Shareholders
From AC Immune SA
Via GlobeNewswire
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease
From AC Immune SA
Via GlobeNewswire
AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline
From AC Immune SA
Via GlobeNewswire
AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
From AC Immune SA
Via GlobeNewswire
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023
From AC Immune SA
Via GlobeNewswire
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
From AC Immune SA
Via GlobeNewswire
AC Immune to Present at the SVB Securities Global Biopharma Conference
From AC Immune SA
Via GlobeNewswire
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
From AC Immune SA
Via GlobeNewswire
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease
From AC Immune SA
Via GlobeNewswire
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
From AC Immune SA
Via GlobeNewswire
AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference
From AC Immune SA
Via GlobeNewswire
Is Ardelyx is A Buy After Slip in Early 2022
Ardelyx is relatively new to the market and was doing well until a small drug approval issue last year. Strong earnings and smart partnerships could save them 
Via MarketBeat
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.